Related Experiment Video
Updated: May 25, 2026
06:37
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma
Ye Cao1, Yan-xia Shi, Jing-ou Chen
1State Key Laboratory of Oncology, South China, Guangzhou, Guangdong 510060, People's Republic of China.
Summary
C-reactive protein (CRP) is a valuable prognostic marker for diffuse large B cell lymphoma (DLBCL). Elevated CRP levels correlate with disease severity and predict patient survival outcomes.
Area of Science:
- Oncology
- Biochemistry
- Clinical Medicine
Background:
- C-reactive protein (CRP) is an acute-phase reactant with potential as a cancer biomarker.
- Diffuse large B cell lymphoma (DLBCL) is a common type of non-Hodgkin lymphoma.
Purpose of the Study:
- To evaluate C-reactive protein (CRP) levels as a prognostic parameter for treatment response and long-term survival in DLBCL patients.
- To correlate CRP levels with clinical data, including the International Prognostic Index (IPI) and clinical stage.
Main Methods:
- Retrospective study of 94 DLBCL patients from October 2006 to August 2009.
- Serum CRP levels were measured and correlated with clinical data, IPI scores, overall survival (OS), and time to progression (TTP).
Main Results:
- Median CRP levels were 30.91 ± 53.35 mg/L in males and 22.39 ± 29.89 mg/L in females.
- Baseline CRP levels correlated with IPI scores (p=0.03), long-term survival in patients with IPI 1-2 (p=0.001), OS (p=0.001), and clinical stage (p=0.03).
- CRP levels after two chemotherapy cycles correlated with short-term treatment response (p=0.003), OS (p=0.04), and TTP (p=0.03).
Conclusions:
- Serum CRP levels serve as an additional prognostic parameter in patients with DLBCL.
- CRP is a useful biomarker for assessing treatment response and predicting survival in DLBCL.
